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Abstract
Intra-abdominal infections are one of the most common gastrointestinal
emergencies and a leading cause of septic shock. A consensus conference
on the management of community-acquired peritonitis was published in 2000.
A new consensus as well as new guidelines for less common situations such
as peritonitis in paediatrics and healthcare-associated infections had become
necessary. The objectives of these Clinical Practice Guidelines (CPGs) were
therefore to define the medical and surgical management of community-acquired
intra-abdominal infections, define the specificities of intra-abdominal infections in
children and describe the management of healthcare-associated infections. The
literature review was divided into six main themes: diagnostic approach, infection
source control, microbiological data, paediatric specificities, medical treatment of
peritonitis, and management of complications. The GRADE(®) methodology was
applied to determine the level of evidence and the strength of rec...
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A B S T R A C T
Intra-abdominal infections are one of the most common gastrointestinal emergencies and a leading
cause of septic shock. A consensus conference on the management of community-acquired
peritonitis was published in 2000. A new consensus as well as new guidelines for less common
situations such as peritonitis in paediatrics and healthcare-associated infections had become
necessary. The objectives of these Clinical Practice Guidelines (CPGs) were therefore to deﬁne the
medical and surgical management of community-acquired intra-abdominal infections, deﬁne the
speciﬁcities of intra-abdominal infections in children and describe the management of healthcare-
associated infections. The literature review was divided into six main themes: diagnostic approach,
infection source control, microbiological data, paediatric speciﬁcities, medical treatment of
peritonitis, and management of complications. The GRADE1 methodology was applied to determine
the level of evidence and the strength of recommendations. After summarising the work of the
experts and application of the GRADE1 method, 62 recommendations were formally deﬁned by the
organisation committee. Recommendations were then submitted to and amended by a review
committee. After 2 rounds of Delphi scoring and various amendments, a strong agreement was
obtained for 44 (100%) recommendations. The CPGs for peritonitis are therefore based on a consensus
between the various disciplines involved in the management of these patients concerning a number
of themes such as: diagnostic strategy and the place of imaging; time to management; the place of
microbiological specimens; targets of empirical anti-infective therapy; duration of anti-infective
therapy. The CPGs also speciﬁed the value and the place of certain practices such as: the place of
laparoscopy; the indications for image-guided percutaneous drainage; indications for the treatment
of enterococci and fungi. The CPGs also conﬁrmed the futility of certain practices such as: the use
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2. Work groups
Experts representing their learned society are designated by the
society’s acronym. Invited experts are designated by their
specialty.
Diagnosis of intra-abdominal infection
J.M. Constantin, Clermont-Ferrand (Sfar)
J. Cazejust, Paris (Radiologist)
E. Gre´goire, Marseille (Surgeon)
M. Leone, Marseille (Sfar)
T. Lescot, Paris (Anaesthetist-Intensive Care Physician)
J. Morel, Saint-E´tienne (Anaesthetist-Intensive Care Physician)
A. Sotto, Nıˆmes (SPILF)
J.J. Tuech, Rouen (AFCD)
Infection source control
P.F. Laterre, Brussels (SRLF)
C. Brigand, Strasbourg (AFC)
S. Lasocki, Angers (Anaesthetist-Intensive Care Physician)
G. Plantefeve, Argenteuil (Intensive Care Physician)
C. Tassin, Lyon (Anaesthetist-Intensive Care Physician)
Contribution of microbiology
R. Gauzit, Paris (SPILF)
P. Augustin, Paris (Anaesthetist-Intensive Care Physician)
A. Friggeri Pierre-Be´nite (Anaesthetist-Intensive Care Physi-
cian)
C. Hennequin, Paris (Mycologist)
Y. Pean, Paris (Microbiologist)
A. Roquilly, Nantes (Anaesthetist-Intensive Care Physician)
P. Seguin, Rennes (Anaesthetist-Intensive Care Physician)
Speciﬁcities of paediatric intra-abdominal infections
K. Asehnoune, Nantes (Anaesthetist-Intensive Care Physician)
C. Daurel, Caen (Microbiologist)
R. Dumont, Nantes (Anaesthetist-Intensive Care Physician)
C. Jeudy, Angers (Anaesthetist-Intensive Care Physician)
S. Irtant, Paris (Surgeon)
Medical treatment of intra-abdominal infections
C. Paugam, Clichy (Anaesthetist-Intensive Care Physician)
J.P. Bru, Annecy (SPILF)
C. Dahyot, Poitiers (Anaesthetist-Intensive Care Physician)
L. Dubreuil, Lille (Microbiologist)
G. Dufour, Paris (Anaesthetist-Intensive Care Physician)
B. Jung, Montpellier (Anaesthetist-Intensive Care Physician)
J. Pottecher, Strasbourg (Anaesthetist-Intensive Care Physician)
Complications of intra-abdominal infections
P.F. Perrigault, Montpellier (Anaesthetist-Intensive Care Physi-
cian)
A. Hamy, Angers (AFC)
N. Kermarrec, Antony (Anaesthetist-Intensive Care Physician)
Y. Launay, Rennes (Anaesthetist-Intensive Care Physician)
B. Misset, Paris (SRLF)
L. Ribeiro Parenti, Paris (Surgeon)
B. Veber, Rouen (Anaesthetist-Intensive Care Physician)
T. Yzet, Amiens (Radiologist)
3. Review committee
K. Asehnoune, Nantes (Anaesthetist-Intensive Care Physician),
P. Augustin, Paris (Anaesthetist-Intensive Care Physician), C. Brigand,
Strasbourg (AFC), J.P. Bru, Annecy (SPILF), J.M. Constantin, Clermont-
Ferrand (Sfar), C. Dahyot, Poitiers (Anaesthetist-Intensive Care
Physician), C. Daurel, Caen (Microbiologist), L. Dubreuil, Lille
(Microbiologist), G. Dufour, Paris (Anaesthetist-Intensive Care
Physician), R. Dumont, Nantes (Anaesthetist-Intensive Care Physi-
cian), H. Dupont, Amiens (Sfar), A. Friggeri, Pierre-Be´nite (Anaesthe-
tist-Intensive Care Physician), R. Gauzit, Paris (SPILF), A. Hamy,
Angers (AFC), C. Hennequin, Paris (Mycologist), C. Jeudy, Angers
(Anaesthetist-Intensive Care Physician), B. Jung, Montpellier (Anaes-
thetist-Intensive Care Physician), N. Kermarrec, Antony (Anaesthe-
tist-Intensive Care Physician), Y. Launay, Rennes (Anaesthetist-
Intensive Care Physician), S. Lasocki, Angers (Anaesthetist-Intensive
Care Physician), P.F. Laterre, Brussels (SRLF), M. Leone, Marseille (far),
T. Lescot, Paris (Anaesthetist-Intensive Care Physician), B. Misset,
Paris (SRLF), P.M. Mertes, Nancy (Sfar), P. Montravers, Paris (Sfar),
J. Morel, St Etienne (Anaesthetist-Intensive Care Physician),
C. Paugam, Clichy (Anaesthetist-Intensive Care Physician), Y. Pean,
Paris (Microbiologist), P.F. Perrigault, Montpellier (Anaesthetist-
Intensive Care Physician), G. Plantefeve, Argenteuil (Intensive Care
Physician), J. Pottecher, Strasbourg (Anaesthetist-Intensive Care
Physician), L. Ribeiro Parenti, Paris (Surgeon), A. Roquilly, Nantes
(Anaesthetist-Intensive Care Physician), P. Seguin, Rennes (Anaes-
thetist-Intensive Care Physician), A. Sotto, Nimes (SPILF), J.J. Tuech,
Rouen (AFCD), B. Veber, Rouen (Anaesthetist-Intensive Care Physi-
cian).
4. Introduction
4.1. Background
The ﬁrst French consensus conference on the management of
community-acquired peritonitis was published in 2000. The
conclusions of this consensus conference needed to be updated
in the light of the abundant literature, a number of international
guidelines that fail to take into account all of the factors speciﬁc to
France, changing practices and surgical techniques, the growth of
bacterial resistance and the availability of new molecules in the
therapeutic armamentarium. Revision of these clinical practice
guidelines was therefore conducted jointly by the Socie´te´ franc¸aise
d’anesthe´sie et de re´animation (Sfar), the learned society that
initiated the ﬁrst consensus conference, the Socie´te´ de re´animation
de langue franc¸aise (SRLF), the Socie´te´ de pathologie infectieuse de
langue franc¸aise (SPIF), the Association franc¸aise de chirurgie and the
Socie´te´ franc¸aise de chirurgie digestive (SFCD).
These updated guidelines had to address the management of
community-acquired peritonitis, one of the most common gastro-
intestinal emergencies, but also had to propose guidelines for less
common infections, for which prescribers often feel at a loss, which
is why the present guidelines are divided into three main topics: the
management of community-acquired infection, intra-abdominal
infections in children and healthcare-associated infections.
of diagnostic biomarkers; systematic relaparotomies; prolonged anti-infective therapy, especially
in children.
 2015 Socie´te´ franc¸aise d’anesthe´sie et de re´animation (Sfar). Published by Elsevier Masson SAS. All
rights reserved.
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4.2. Objectives of the CPGs
The objectives of these Clinical Practice Guidelines (CPGs) are to:
 deﬁne the medical and surgical management of community-
acquired intra-abdominal infections;
 deﬁne the speciﬁcities of management of intra-abdominal
infections in children;
 describe the medical and surgical management of healthcare-
associated intra-abdominal infections.
4.3. Deﬁnitions
This subject is so vast that it would be impossible to
comprehensively address all forms of gastrointestinal infectious
disease. These updated guidelines exclusively concern peritonitis
requiring surgical management and do not concern so-called
primary infections complicating cirrhosis, or focal infections such
as biliary tract infections, isolated hepatic abscess or sigmoid
diverticulitis infections.
Common sense elements constituting the basis for good quality
medicine were not analysed. The experts highlighted several
essential points with which all practitioners must be familiar and
which do not correspond to conventional updated guidelines:
 the source of infection must be systematically and urgently
eradicated by complete peritoneal toilet regardless of the
surgical technique performed (laparotomy or laparoscopy);
 initiation of anti-infective therapy must never be delayed until
peritoneal ﬂuid microbiological samples have been obtained;
 regardless of the situation (community-acquired or nosocomial
peritonitis), samples must not be taken from close succion drains
and drainage systems because their results are uninterpretable;
 regardless of the results of microbiological samples in commu-
nity-acquired or nosocomial peritonitis, the antibiotic spectrum
must cover anaerobic bacteria.
In accordance with current guidelines on severe sepsis and
septic shock, the experts deﬁned a serious form of peritonitis as the
presence of at least two of the following clinical manifestations in
the absence of another cause:
 hypotension attributed to sepsis;
 serum lactic acid higher than the laboratory’s normal values;
 Diuresis < 0.5 mL/kg/h for more than 2 hours despite appropri-
ate IV ﬂuid therapy;
 PaO2/FiO2 ratio < 250 mmHg in the absence of pneumonia;
 serum creatinine > 2 mg/dL (176.8 mmol/L);
 serum bilirubin > 2 mg/dL (34.2 mmol/L);
 thrombocytopenia < 100,000/mm3.
Very few data are available in the literature concerning intra-
abdominal infections in critically ill patients requiring intensive
care management, which left the experts with the choice between
two solutions: either to propose no guidelines due to the absence
of evidence or to propose guidelines based on other guidelines or
by extrapolation with other similar situations. The experts chose
this second option in order to provide guidance for prescribing
physicians. Consequently, all recommendations concerning the
management of patients in shock are based on the guidelines of the
SFAR consensus conference on this subject.
All of the literature published since 1999, the date of the ﬁrst
consensus conference, and that published prior to 1999 and
considered to be relevant by the experts was analysed. Many of the
topics discussed in these guidelines are based on limited scientiﬁc
evidence, for example intra-abdominal infections in children for
which recommendations are extrapolated from the results
obtained in adults. Recommendations concerning anti-infective
therapy are also based on only a limited number of studies. No
study has evaluated the effects of antifungal therapy in peritonitis
and only a few publications have reported the dosage of anti-
infective agents and the results of pharmacokinetic studies in these
infectious sites. The recommended durations of treatment are
currently based on expert opinion until the results of ongoing
studies have been published. These various elements, reﬂecting a
low level of scientiﬁc evidence, account for the large number of
cautious recommendations. Each question was addressed inde-
pendently of the others, leading to the writing of recommendations
validated by the GRADE1method. The reader is therefore advised
to refer to the literature review tables presented as appendix on the
web site (http://www.sfar.org/_docs/articles/Classementdestudes
RFEintraabdo-versionﬁnalise.xls).
4.4. Methodology
The GRADE1 method was used to establish these guidelines.
Following quantitative analysis of the literature, this method can
be used to separately determine the quality of evidence, i.e.
estimation of the level of conﬁdence of the analysis of the effect of a
quantitative intervention, and the grade of recommendation.
Quality of evidence was classiﬁed into four categories:
 high: future research will very probably not change the level of
conﬁdence in the estimate of the effect;
 moderate: future research will probably change the level of
conﬁdence in the estimate of the effect and could modify the
estimate of the effect itself;
 low: future research will very probably have an impact on the
level of conﬁdence in the estimate of the effect and will probably
modify the estimate of the effect itself;
 very low: the estimate of the effect is very uncertain.
Analysis of the quality of evidence was performed for each
study and a global level of evidence was then deﬁned for a
particular question and a particular criterion.
The ﬁnal formulation of the recommendations is always binary,
either positive or negative and either strong or weak:
 strong: It must be done or must not be done (GRADE 1+ or 1–);
 weak: It can be either done or not done (GRADE 2+ or 2–).
The strength of recommendation was determined according to
key factors, validated by the experts after a vote, using the Delphi
method:
 estimate of the effect;
 the global level of evidence: the higher the level of evidence, the
more likely the recommendation will be strong;
 the balance between desirable and adverse effects: the more
favourable this balance, the more likely the recommendation
will be strong;
 values and preferences: the recommendation is more likely to be
weak in the case of uncertainty or marked variability; these
values and preferences must ideally be determined directly with
the people concerned (patient, doctor, decision-maker);
 costs: the higher the costs or the use of resources, the more likely
the recommendation will be weak.
Management of intra-abdominal infections was analysed
according to 5 themes: preoperative diagnosis, infection source
control, information provided by microbiology, medical treatment
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of intra-abdominal infections, complications of intra-abdominal
infections. Elements speciﬁc to community-acquired infections
and postoperative infections were identiﬁed for each theme.
Paediatric infections were analysed speciﬁcally. A total of
40 experts participated in 6 work groups.
Only articles published after 1999 were included in the analysis.
When only a small number or even no articles were published
during the period considered, the search period was able to be
extended until 1990.
The methodology of the published studies on intra-abdominal
infections is generally subject to criticism. The experts were
therefore faced with three situations:
 for some questions, several methodologically satisfactory studies
and/or meta-analyses were available, allowing complete appli-
cation of the GRADE1method and formulation of recommenda-
tions. Only several recommendations were based on a meta-
analysis;
 when a meta-analysis was not available to allow the experts to
answer the question, qualitative analysis according to the
GRADE1 method was possible and a systematic review was
performed. A limited number of recommendations were based
on quantitative analysis due to the poor quality of the published
data and the limited information available;
 ﬁnally, in certain ﬁelds, the absence of any recent studies did not
allow the formulation of any recommendations.
Overall, for a large part of this work, the GRADE1method did not
appear to be applicable and only expert opinions could be proposed.
After summarising the work of the experts and application of
the GRADE1 method, 62 recommendations were initially formu-
lated by the guidelines committee.
All recommendations were submitted to a review committee
for Delphi scoring. The review committee was composed of
38 anaesthetists-intensive care physicians, surgeons, infectious
disease specialists, microbiologists, and mycologists who had
already participated in a work group, as well as several other
reviewers. After 2 rounds of Delphi scoring and various amend-
ments, 18 recommendations were abandoned or reformulated. A
strong agreement was obtained for 44 (100%) recommendations,
corresponding to the guidelines presented below. Ten recommen-
dations were considered to be strong (Grade 1 positive or negative)
and 25 were considered to be weak (Grade 2 positive or negative),
while the GRADE1method could not be applied to 9 recommenda-
tions, which therefore correspond to expert opinions.
5. Recommendations for community-acquired intra-
abdominal infections
Although many clinical trials have been devoted to the
management of community-acquired intra-abdominal infections,
they were very often purely observational and are unable to
answer all of the questions raised. Clinical practices associated
with a high-level of agreement of the experts are often based on
common sense or usual practice and cannot be readily justiﬁed by
randomized clinical trials.
Only limited French and European data are available concerning
the epidemiology of bacterial resistance in community-acquired
intra-abdominal infections. The speciﬁcity of the epidemiology of
bacterial resistance in this setting does not allow clinical practice
guidelines to be extrapolated from those proposed in other
settings, such as urinary tract infections. The epidemiology of
bacterial resistance also differs between community-acquired
infections and healthcare-associated infections, leading to speciﬁc
conclusions and recommendations. First-line use of carbapenems
is strongly discouraged due to the risk of emergence of resistance.
No studies have been published on several topics since the ﬁrst
guidelines published in 2000. These guidelines therefore cannot be
updated. The guidelines committee consequently decided to
maintain these important recommendations unchanged.
An example of such a recommendation concerns the duration of
anti-infective therapy for perforated gastric or duodenal ulcer
operated within 24 hours after the diagnosis. The recommended
duration of antibiotic therapy is 24 hours.
Similarly, in penetrating abdominal wounds with opening of the
gastrointestinal tract and iatrogenic perforations below transverse
mesocolon, 24 hours of antibiotic therapy is recommended when
surgery is performed within 12 hours after the injury.
5.1. How can the diagnosis of IAI be established?
Place of imaging in the diagnosis of peritonitis
R1 – Imaging is probably not required in the case of suspected
peritonitis due to organ perforation in a critically ill patient
(according to the definition indicated in the introduction) if it
delays the surgical procedure.
(Expert opinion) STRONG agreement
Rationale:Thestudiesthat demonstrated the valueof imaging
examinations focused on appendicitis. Patients with suspected
intra-abdominal infectiondue to organ perforationoften present
with typical clinical features comprising rapid onset of abdomi-
nal pain and gastrointestinal signs (anorexia, nausea, vomiting,
constipation) with or without signs of peritoneal inflammation
(guarding, rigidity) and systemic signs (fever, tachycardia, and/
or tachypnoea). Physical examination and clinical history are
usually sufficient to establish a limited number of differential
diagnoses and todetermine thedegreeofseverityof the disease.
These findings guide the immediate decisions concerning rehy-
dration/resuscitation, complementary diagnostic procedures,
and the need for curative antibiotic therapy and emergency
surgery. The timing and the nature of the percutaneous or
surgical procedure are defined on the basis of these decisions.
When the infection is poorly tolerated, an imaging examination
would only be useful when it is immediately available and in
order to guide the surgical procedure.
R2 – When peritonitis due to perforated gastroduodenal ulcer
is suspected, the indication for surgery can be based on
clinical history and the presence of pneumoperitoneum on a
plain abdominal X-ray.
(Expert opinion) STRONG agreement.
Rationale: The studies that demonstrated the value of imag-
ing examinations focused on appendicitis. The presence of
clinical features suggestive of perforated gastroduodenal ulcer
associated with the presence of pneumoperitoneum on a plain
abdominal X-ray film is sufficient to constitute a formal indi-
cation for immediate surgery. Complementary imaging exam-
inations would only be useful when they are immediately
available and in order to guide the surgical procedure.
5.2. How can infection source control be ensured? When should the
patient be treated?
R3 – A patient with suspected peritonitis due to organ
perforation must be operated as rapidly as possible, especially
in the presence of septic shock.
(Grade 1+) STRONG agreement
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Rationale: Most of the available guidelines emphasize the
need for immediate surgery once the diagnosis has been
established. No prospective study has validated this approach.
Retrospective studies have demonstrated an association be-
tween delayed surgery and excess mortality, including on
multivariate analysis for the majority of these studies [1–
5]. Patients with peritonitis complicated by septic shock (about
40% of all intra-abdominal infections [IAI]) present an excess
mortality and morbidity compared to patients without shock
[6–8]. It seems reasonable to propose resuscitation prior to
surgery (IV fluid therapy, conditioning, etc.) without delaying
surgery after achieving haemodynamic stabilization of shock,
as recommended by the SFAR consensus conference on the
management of septic shock [9].
5.3. What are the indications for laparoscopy?
R4 – Laparoscopy should probably not be used for the
treatment of peritonitis due to perforated peptic ulcer in a
patient presenting more than one of the following risk factors:
state of shock on admission, ASA score III–IV, and presence of
symptoms for more than 24 hours.
(Grade 2–) STRONG agreement
Rationale: The Boey score attributes one point to the follow-
ing risk factors: shock on admission, ASA score III-IV, symp-
toms present for more than 24 hours. In a meta-analysis
combining 56 publications and 2784 patients, the authors
concluded that laparoscopy was a safe procedure in patients
with a Boey score of 0 or 1 [10]. According to these authors,
laparoscopy is contraindicated in patients with a Boey score of
2 or 3 due to the very high morbidity and mortality [10].
R5 – Laparoscopy should not be performed in the case of
purulent peritonitis due to diverticulosis (Hinchey IV) or
generalized peritonitis.
(Grade 1–) STRONG agreement
Rationale: No randomized prospective study has compared
laparoscopy and laparotomy in perforated sigmoid diverticu-
litis. Eleven studies comprising a total of 276 cases of Hinchey II
(pelvic abscess < 4 cm away from the colon) and Hinchey III
peritonitis (purulent) treated by laparoscopic lavage and drain-
age reported a morbidity rate of 10.5%. Laparoscopy is not
recommended in purulent peritonitis (Hinchey IV) [11] due to a
7-day reoperation rate of 37% [12–15].
5.4. What is the place of image-guided percutaneous drainage?
R6 – In the absence of haemodynamic instability (defined as
the need for more than 0.1 mg/kg/min of epinephrine or
norepinephrine), the decision to perform first-line image-
guided percutaneous drainage for the management of intra-
abdominal abscess in the absence of clinical or radiological
signs of perforation and to allow microbiological examination
of peritoneal fluid samples should probably be based on a
multidisciplinary discussion.
(Grade 2+) STRONG agreement.
Rationale: The use of interventional radiology for the man-
agement of IAI must be based on multidisciplinary collabora-
tion (intensive care physician, surgeon and radiologist). The
global efficacy of drainage of intra-abdominal collections is
reported to be 70 to 90% [16,17]. Few studies have compared
surgery to drainage of infected intra-abdominal collections
[18]. Lower mortality was reported in the group treated by
image-guided percutaneous drainage vs. surgery [18]. Good
indications are liver abscess (high-risk of rupture), diverticular
abscess, postoperative abscess or abscess complicating
Crohn’s disease. Indications to be discussed case by case
are superinfection of a fluid collection following acute pancre-
atitis, appendicular and splenic abscesses, and cholecystitis.
Free effusions and collections with a large gastrointestinal
fistula (anastomotic leak) are poor indications. The indication
for image-guided percutaneous drainage may need to be
revised in the presence of severe sepsis with multiple organ
failure.
R7 – Drainage should be checked by CT scan in the presence of
signs of deterioration.
(Grade 1+) STRONG agreement
Rationale: The global efficacy of drainage of intra-abdominal
collections is reported to be 70 to 90% [16,17]. In a series of
956 cases of drainage, Gervais et al. [19] reported 45 abscesses
requiring a second drainage procedure (4.9% of cases). These
authors recommended surveillance of drainage several times a
day, with CT scan on removal of the drain and in the case of an
unusual course [19]. Drain obstructions and fistulas are the
most common causes of failure [19,20].
5.5. What is the place of relaparotomies?
R8 – When surgical treatment is considered to be satisfactory
(source control, lavage), relaparotomies should not be
systematically planned.
(Grade 1–) STRONG agreement
Rationale: The surgical strategy of systematic (or planned)
relaparotomy consists of reoperating patients every 24 to
48 hours until the intraoperative findings conclude on the
absence of persistent sepsis. Retrospective [21–23] or non-
randomized studies [24] presented multiple biases and
reported discordant results. A multicentre randomized pro-
spective study in adults showed a prolonged intensive care and
hospital stay with no survival benefit and no reduction of the
number of major complications with systematic relaparo-
tomies [25].
5.6. How should microbiology results be interpreted? When and how
should microbiological samples be obtained?
R9 – Peritoneal fluid samples are probably necessary in
community-acquired IAI in order to identify the microorga-
nisms and determine their susceptibility to anti-infective
agents.
(Grade 2+) STRONG agreement
Rationale: When the patient has not received any antibiotics
during the previous 3 months [26], the microorganisms most
likely responsible can be easily predicted (Escherichia coli,
Klebsiella spp. Bacteroides sp, Clostridium sp, Peptostrepto-
coccus sp, Streptococcus sp). Microbiological cultures of sur-
gical samples (fluid or pus) and blood cultures and antibiotic
susceptibility testing are optional. When the patient has re-
cently received antibiotics (last 3 months) for at least 2 days,
peritoneal fluid and pus samples and blood cultures are
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justified [26]. However, there is no formal evidence that all of
the bacteria isolated need to be taken into account in the anti-
infective therapy. Except in the case of critically ill patients with
septic shock, the need to subsequently adapt empirical antibi-
otic therapy has also not been formally demonstrated.
Epidemiological and community microbiological surveil-
lance is recommended. Individual sampling is necessary in
a context of emergence of high-level penicillinase-producing
or ESBL-producing E. coli strains [7,26–28]. A single sample is
sufficient in the case of a free peritoneal effusion, but multiple
samples must be taken in the case of multiple peritoneal
abscesses.
R10 – Blood cultures and direct examination of peritoneal fluid
looking for yeasts must be performed in septic shock and/or
immunodepressed patients with community-acquired IAI.
(Grade 1+) STRONG agreement
Rationale: Patients with peritonitis complicated by septic
shock (about 40% of all intra-abdominal infections [IAI]) pres-
ent an excess mortality and morbidity compared to patients
without shock [6–8]. No published studies have formally dem-
onstrated the need to perform blood cultures and direct
examination of peritoneal fluid. Variable blood culture rates
are reported, up to 22% of cases for Gauzit et al. [27]. Dupont
reported an excess mortality when direct examination of
peritoneal fluid was positive for yeasts [29]. In the presence
of septic shock or severe sepsis, inappropriate anti-infective
therapy (not covering all of the microorganisms isolated) is
regularly associated with increased morbidity and mortality
[30] as well as increased costs [31]. It seems reasonable to
propose microbiological and mycological documentation
without delaying empirical anti-infective therapy, as recom-
mended by the SFAR consensus conference on the manage-
ment of septic shock [9].
5.7. How should empirical antibiotic therapy be targeted?
R11 – Empirical antibiotic therapy protocols for community-
acquired IAI must be established on the basis of regular
analysis of national and regional microbiological data in order
to quantify and monitor the course of microbial resistance in
the community.
(Grade 1+) STRONG agreement
Rationale: In view of the potential difficulty of selecting
appropriate anti-infective therapy, local and regional antibiotic
therapy protocols must be established on the basis of the
community origin, patient characteristics (comorbidities), clini-
cal severity, presence of documented beta-lactam allergy and by
taking local bacterial resistance data into account [7,26–
28]. These protocols must be elaborated by multidisciplinary
teams (anaesthetists-intensivecarephysicians,microbiologists,
surgeons, infectious disease specialists and pharmacists).
R12 – E. coli strains resistant to third-generation-cephalospo-
rins should probably not be taken into account in community-
acquired infections with no signs of severity, except for
particular local or regional epidemiological conditions (> 10%
resistance of strains) or when the patient has spent time in
geographical zones with a high prevalence of MDR bacteria.
(Grade 2–) STRONG agreement
Rationale: The percentage susceptibility to amoxicillin/
clavulanic acid (AMC) of Enterobacteriaceae isolated from
community-acquired peritonitis in adults in France is about
55 to 70% [7,26–28]. However, 90 to 100% of these AMC-
resistant Enterobacteriaceae remain susceptible to aminogly-
cosides, third-generation cephalosporins, and fluoroquino-
lones [7,28]. In France, the prevalence of extended-spectrum
beta-lactamase-producing Enterobacteriaceae (ESBL-E) in
samples from adults with community-acquired peritonitis is
low and these organisms must not be taken into account in
empirical antibiotic therapy, except in the case of particular
local or regional epidemiological conditions. These ecological
conditions can rapidly change. At the present time, a risk of
bacteria that are difficult to treat is observed in Asia and in the
Indian subcontinent [32]. In Europe, patients from Eastern
Mediterranean countries are potential sources of ESBL-E or
even carbapenemase-producing strains [33].
R13 – In view of the changing susceptibility profiles of
Bacteroides spp., clindamycin and cefoxitin must not be used
as empirical therapy in community-acquired IAI.
(Grade 1–) STRONG agreement
Rationale: More than 50% of Bacteroides fragilis strains
have become resistant to cefoxitin, cefotetan (cephalosporin
generally reserved for prophylaxis) and clindamycin. These
agents can no longer be recommended for empirical therapy.
The susceptibility of anaerobes to penicillins + inhibitors
(amoxicillin/clavulanic acid, ticarcillin/clavulanic acid, piper-
acillin/tazobactam), carbapenems (ertapenem, imipenem,
meropenem) and nitroimidazoles (metronidazole) is pre-
served [7].
5.8. Should yeasts be taken into account in anti-infective therapy?
R14 – Empirical therapy active against Candida should not be
initiated in community-acquired IAI in the absence of signs of
severity.
(Grade 1–) STRONG agreement
Rationale: The data of the literature show that it is unneces-
sary to institute empirical antifungal therapy for community-
acquired peritonitis in the absence of signs of severity, except
in immunodepressed patients, transplant recipients or patients
with an inflammatory disease [34–36].
R15 – Antifungal therapy should probably be initiated in
severe peritonitis (community-acquired or postoperative), in
the presence of at least 3 of the following criteria: haemo-
dynamic failure, female gender, upper gastrointestinal sur-
gery, antibiotic therapy for more than 48 hours.
(Grade 2+) STRONG agreement
Rationale: In severe peritonitis, the presence of yeasts is a
factor of poor prognosis [8]. The presence of yeasts on direct
examination of peritoneal fluid indicates the presence of a
large inoculum and is associated with excess mortality
[29]. Clinical features suggestive of yeast infection are haemo-
dynamic failure, upper gastrointestinal perforation, female
gender and antibiotic therapy during the previous 48 hours
[37]. When 3 of these 4 criteria are present, the probability of
isolating Candida in peritoneal fluid is 71%. No prospective
study has formally validated the rationale for antifungal thera-
py. Nevertheless, in view of the clinical severity, it appears
reasonable to initiate empirical antifungal therapy in this
setting.
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5.9. Should enterococci be taken into account in anti-infective
therapy?
R16 – Enterococci should probably not be taken into account
in empirical antibiotic therapy for community-acquired IAI
with no signs of severity.
(Grade 2–) STRONG agreement
Rationale: Enterococci are isolated in 5 to 20% of cases of
community-acquired peritonitis. Their pathogenicity remains
controversial, but they could be responsible for excess morbidi-
ty (higher rate of extraperitoneal postoperative infectious com-
plications and intraperitoneal abscess formation), while their
impact on mortality remains hypothetical [4,7,27,38–40]. There
is no formal evidence to justify taking enterococci into account in
the choice of empirical antibiotic therapy, except in targeted
populations such as elderly or immunodepressed subjects
[39,40].
5.10. Which empirical anti-infective therapy should be proposed and
in which patients?
R17 – One of the following antibiotic regimens should probably
be used as first-line therapy: (1) amoxicillin/clavulanic acid +
gentamicin; (2) cefotaxime or ceftriaxone + metronidazole.
(Grade 2+) STRONG agreement
Rationale: First-line empirical therapy for IAI with no signs of
severity must target Enterobacteriaceae and anaerobic bacte-
ria. Enterobacteriaceae isolated from cases of community-
acquired peritonitis in adults in France are susceptible to
amoxicillin/clavulanic acid (AMC) in > 75% of naturally sus-
ceptible strains [7,26]. AMC-resistant Enterobacteriaceae re-
main susceptible to aminoglycosides and third-generation
cephalosporins in 90 to 100% of cases [7]. In France, the
prevalence of extended-spectrum beta-lactamase-producing
Enterobacteriaceae (ESBL-E) in samples from community-ac-
quired peritonitis in adults is low and these organisms must
not be taken into account in empirical antibiotic therapy, except
in the case of particular local or regional epidemiological
conditions. Fluoroquinolones are not recommended as first-
line therapy due to a higher rate of resistance [7].
R18 – A combination of levofloxacin + gentamicin + metroni-
dazole or, in the absence of any other treatment option,
tigecycline should probably be used in community-acquired
infections in patients with documented beta-lactam allergy.
(Expert opinion) STRONG agreement
Rationale: First-line empirical therapy for IAI with no signs of
severitymust targetEnterobacteriaceaeand anaerobesbacteria.
Only limited data on this subject are available in the literature.
Most guidelines indicate several possible treatment options, but
the general impression is that, in the absence of good quality
publications in this field, an alternative must be proposed to
avoid leaving the clinician with no treatment options. No clinical
trial supports theuse ofthese agents inpatients withbeta-lactam
allergy. A combination of fluoroquinolones (ciprofloxacin, levo-
floxacin or moxifloxacin) and gentamicin can be used to treat
resistant Enterobacteriaceae [41–44]. The addition of a nitroi-
midazole (metronidazole) is essential to target anaerobic bacte-
ria, except when moxifloxacin is used to target these bacteria.
Tigecycline is an alternative in the absence of any other
options. This agent is active against Enterobacteriaceae includ-
ing ESBL-producing strains but not against Proteae (Proteus sp.
and Morganella sp.) or Pseudomonas [45–48]. It probably has a
place in moderately severe community-acquired infections.
R19 – In severe IAI, empirical antibiotic therapy must be
adapted to the suspected organisms.
(Grade 1+) STRONG agreement
Rationale: Patients with peritonitis complicated by septic
shock (about 40% of all intra-abdominal infections [IAI]) pres-
ent an excess mortality and morbidity compared to patients
without shock [6,8]. In the presence of septic shock or severe
sepsis, inappropriate anti-infective therapy (not covering all of
the microorganisms isolated) is regularly associated with
increased morbidity and mortality [30,49] as well as increased
costs [31,50]. A poorer survival rate is reported in case of
delayed adaptation of empirical therapy to the results of
antibiotic susceptibility testing [51].
R20 – Piperacillin/tazobactam plus or minus gentamicin
should probably be used in critically ill patients with
community-acquired IAI.
(Grade 2+) STRONG agreement
Rationale: In the presence of septic shock or severe sepsis,
inappropriate anti-infective therapy (not covering all of the
microorganisms isolated) is regularly associated with in-
creased morbidity and mortality [30,49,52]. The percentage
susceptibility to amoxicillin/clavulanic acid (AMC) of Enter-
obacteriaceae isolated from adults with community-
acquired peritonitis in France is > 75% of naturally suscepti-
ble strains, while 96 to 100% of strains are susceptible to
piperacillin-tazobactam [7]. Combination antibiotic therapy
is justified to extend the spectrum of activity in order to
minimize the risk of therapeutic impasse (for example resis-
tance of E. coli to amoxicillin/clavulanic acid). No study has
specifically evaluated peritonitis associated with septic
shock. Only one good quality study focusing on severe
community-acquired intra-abdominal infections with severe
sepsis failed to demonstrate any benefit of combination
antibiotic therapy [53]. In the presence of septic shock,
the addition of an aminoglycoside could ensure a broader
spectrum of action.
R21 – When it is decided to prescribe empirical antifungal
therapy in a critically ill patient with community-acquired or
healthcare-associated IAI, an echinocandin should probably
be used.
(Expert opinion) STRONG agreement
Rationale: The empirical antibiotic therapy strategy is
based on identification of the species, local and regional
epidemiology, history of recent treatment (3 months) with an
azole antibiotic, clinical severity and known possible coloni-
zation. An echinocandin should be preferred in a critically ill
patient, recent exposure to azole antibiotics (3 months) and
the presence of risk factors for C. glabrata or C. krusei
infection. First-line fluconazole therapy remains indicated
in the other cases [54]. However, no study has specifically
evaluated the efficacy of antifungal therapy in intra-abdomi-
nal infections.
R22 – In a patient treated for community-acquired or
healthcare-associated IAI, antibiotic and antifungal therapy
should probably be de-escalated after reception of the
microbiology and mycology identification and susceptibility
testing results (to adapt treatment in order to obtain the
narrowest therapeutic spectrum).
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(Grade 2+) STRONG agreement
Rationale: Three retrospective, single-centre, observational
studies have described de-escalation practices [55–57]. These
studies included between 60 and 216 patients, 10 to 38% of
whom presented peritonitis. The observed de-escalation rate
was 34 to 45%. In multivariate analysis, the presence of
peritonitis was associated with a lower de-escalation rate,
while appropriate empirical antibiotic therapy was associated
with a higher de-escalation rate. Although de-escalation
appears to be reasonable when empirical therapy was adapted
to the microbiological culture results and when the patient
presents a favourable clinical course, this strategy is based on
only a few methodologically weak studies and should be
evaluated by multicentre randomized prospective trials.
5.11. For how long should anti-infective therapy be administered?
R23 – Antibiotic therapy should probably be administered for
2 to 3 days in localized community-acquired IAI.
(Grade 2+) STRONG agreement
Rationale: The great majority of guidelines concerning the
duration of antibiotic therapy are based on studies with low
levels of evidence and expert opinions. In mild-to-moderate
community-acquired peritonitis, there are many arguments in
favour of brief antibiotic therapy (< 5 days). This duration must
be adapted to the degree of contamination observed intrao-
peratively and optimal surgical infection source control must
be ensured. Most of the studies supporting these guidelines
are now old and comprised a large proportion of appendicular
infections [58]. However, these findings were supported by a
randomized trial published in 2007 that concluded that a
shorter duration of ertapenem (3 days) was as effective as
treatment for  5 days in mild-to-moderate community-ac-
quired peritonitis [59].
R24 – Antibiotic therapy should probably be administered for
5 to 7 days in generalized community-acquired IAI.
(Grade 2+) STRONG agreement
Rationale: The optimal duration of treatment for serious
community-acquired peritonitis has not been established and
is only based on expert opinions. This duration probably
depends on the patient’s comorbidities, the severity of organ
failures, the time to return of bowel movements and the quality
of the surgical procedure. Prospective studies need to be
conducted on this subject. Return of bowel movements, return
to apyrexia, lowering of the leukocyte count and correction of
organ failures are criteria classically used to evaluate the
efficacy of treatment [59–61].
6. Recommendations for paediatric intra-abdominal infections
Very few clinical studies, often consisting of poor quality
observational studies, have been published in the literature and
cannot be used as a basis for clear and deﬁnitive diagnostic or
therapeutic clinical practice guidelines.
There are no radiological or laboratory diagnostic features
speciﬁc to children.
The data of the literature are insufﬁcient to recommend one
particular antibiotic therapy rather than another. Nevertheless,
empirical therapy must comprise an antibiotic active on
Gram-negative bacilli and anaerobic bacteria, such as the
amoxicillin/clavulanic acid or piperacillin/tazobactam combina-
tions. The choice of empirical therapy may be guided by the local
bacterial ecology of E. coli (resistance to amoxicillin/clavulanic
acid). The ototoxicity of aminoglycosides in children must be kept
in mind. Carbapenems should not be used as ﬁrst-line empirical
therapy due to the risk of emergence of resistance, especially
ertapenem due to its lack of efﬁcacy on Pseudomonas aeruginosa
and enterococci.
R25 – Non-irradiating imaging examinations should be
preferred in children.
(Grade 1+) STRONG agreement
Rationale: Studies that have tried to identify diagnostic
criteria predictive of IAI failed to identify any such criteria
[62,63]. A combination of clinical, laboratory (nonspecific
inflammatory syndrome) and radiological arguments can
guide the clinician’s diagnosis and operative indications. Clin-
ical assessment and ultrasound nevertheless play an important
role in the management of IAI and the irradiation of CT scan
should be avoided as far as possible.
R26 – P. aeruginosa should probably be taken into account in
the presence of criteria of severity (organ failure, comorbidi-
ties) or treatment failure.
(Grade 2+) STRONG agreement
Rationale: Several studies have reported a higher inci-
dence of P. aeruginosa, between 5 and 20%, in children,
while this microorganism is less common in adults (except
in the case of nosocomial peritonitis) [64–68]. Although the
pathogenicity of this microorganism has never been formal-
ly demonstrated, and although, in the majority of cases, it is
isolated in combination with other microorganisms, it nev-
ertheless appears important to take P. aeruginosa into
account in 2 situations: when the child has been exposed
to antibiotics during the 3 months prior to surgery, and in the
case of an unfavourable course after 72 hours of well con-
ducted antibiotic therapy.
R27 – The duration of antibiotic therapy should probably not
be longer than that recommended in adults.
(Grade 2–) STRONG agreement
Rationale: Recommended treatment durations in children
are at least 3 to 5 days longer than those recommended in
adults with no evidence-based justification. The shortest
recommended treatment duration for perforated appendicitis
is 48 hours in adults [60] and 5 days in children [61,69]. In most
studies, children with perforated appendicitis are treated for
10 days. A French clinical practice survey of peritonitis (98.5%
of appendicular peritonitis, 76% of which were localized)
revealed a mean duration of antibiotic therapy of 14 days,
including 7 days of oral antibiotics at home [64].
7. Recommendations for healthcare-associated intra-
abdominal infections (nosocomial and postoperative)
The literature on healthcare-associated infections is predom-
inantly devoted to postoperative peritonitis and is very often
based on observational studies. Many questions remain totally
unexplored. Clinical practice guidelines, for which a strong
agreement was reached by the experts, are often based on
extrapolation from management practices in other diseases such
as septic shock.
French data concerning the epidemiology of bacterial resistance
are based on studies published by several teams over the last
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ﬁfteen years. The epidemiology of healthcare-associated infections
differs from that of community-acquired infections, resulting in
speciﬁc conclusions and guidelines. No guidelines can be
established for persistent and/or recurrent multi-operated infec-
tions (often described as tertiary peritonitis) due to the very
limited data available in the literature.
7.1. How can the diagnosis of healthcare-associated IAI be
established?
R28 – A diagnosis of IAI should probably be considered in the
case of development or deterioration of organ dysfunction
during the days following abdominal surgery.
(Grade 2+) STRONG agreement
Rationale: There is little doubt about the diagnosis of IAI in the
presenceof clinical signs suchas severe shock, incisional hernia,
orpurulent orpurulent dischargefrom the laparotomy wound or
in the drains. Apart from these extreme situations, the diagnosis
of IAI and the decision to perform relaparotomy are based on the
team’s experience and a combination of clinical, laboratory and
radiological criteria, which, taken separately, do not have any
positive predictive value for reoperation.
Van Ruler et al. failed to identify a score predictive of persistent
intra-abdominal infection (SOFA, APACHE II, Mannheim Perito-
nitis Index or MODS) [70], while Paugam-Burtz et al. [71] pro-
posed longitudinal daily monitoring of the SOFA score, which
provided a fairly good prediction of persistent infection.
R29 – Relaparotomy should probably be considered on the
fourth or fifth day after the index operation in the absence of
any signs of clinical or laboratory improvement.
(Grade 2+) STRONG agreement
Rationale: In the study by Van Ruler et al. [25] devoted to
planned or on-demand relaparotomies for persistent infection,
the decision to reoperate was based on either deterioration of
the MODS score (Multiple Organ Dysfunction Score) by more
than 4 points or absence of improvement of this score during
the 48 hours following index surgery, or demonstration of a
collection inaccessible to percutaneous drainage. According to
Paugam-Burtz et al. [71], this 48-hour interval was indicative of
persistent intra-abdominal infection. This > 48-hour interval
was also reported to be a risk factor of mortality in the studies
by Koperna [72] and Mulier [22].
R30 – Relaparotomy should be considered in the presence of
postoperative signs of severity after abdominal surgery with
no other obvious cause.
(Grade 2+) STRONG agreement
Rationale: The essential challenge of the relaparotomy strat-
egy is to accurately identify patients requiring relaparotomy
without delaying reoperation [72,73]. The need for relaparot-
omy is obvious in certain clinical settings. Apart from these
extreme situations, the decision to perform relaparotomy is
based on a combination of clinical, laboratory and radiological
criteria, which, taken separately, do not have any positive
predictive value for reoperation and the team’s experience.
It has been demonstrated that when the decision to perform
relaparotomy was taken jointly by surgeons and intensive care
physicians, a surgically accessible cause was identified in 83%
of cases [73]. When the indication for relaparotomy remained
doubtful, imaging (CT and ultrasound) was contributive in only
50% of cases.
R31 – In the case of postoperative abscess, the benefit-risk
balance of image-guided percutaneous drainage versus
relaparotomy should be assessed by a multidisciplinary team
and first-line diagnostic image-guided fine-needle aspiration
should probably be proposed for microbiological examination
of intra-abdominal collections and when there is a doubt
about the diagnosis.
(Grade 2+) STRONG agreement
Rationale: The global efficacy of percutaneous drainage of
intra-abdominal collections is about 70 to 90% of cases
[16]. Few studies have compared surgery to percutaneous
drainage of infected intra-abdominal collections. These stud-
ies were retrospective with heterogeneous inclusion and
success criteria [18]. Decreased mortality was reported in
the group treated by image-guided percutaneous drainage
vs surgery [18]. Image-guided percutaneous drainage
should generally be decided on the basis of a multidisciplin-
ary discussion (intensive care physician, surgeon and radi-
ologist). However, not all abdominopelvic collections are
abscesses. Diagnostic fine-needle aspiration can be per-
formed for bacteriological examination of small collections
(less than 3 cm), or when there is a doubt about the nature of
the collection. The indication for image-guided percutane-
ous drainage may need to be revised in the presence of
severe sepsis with multiple organ failure. The main contra-
indications are severe clotting disorders and the absence
of anatomical access. Infected haematomas and secondarily
infected necrotic tumours classically do not constitute
good indications for percutaneous drainage because of
the frequent obstruction of drain orifices (clots, necrotic
debris) and the risk of life-long palliative drainage for
infected tumours. Finally, the presence of an abscess
does not exclude the presence of adjacent peritonitis or
anastomotic leak [74,75]. According to various series, the
size of the collection (< 5 cm) [76] and the presence of a
fistula (intestinal or biliary) [20] are risk factors for failure of
drainage.
R32 – Contrast-enhanced computed tomography of the
abdomen and pelvis should probably be performed when
postoperative peritonitis is suspected in a stable patient.
Opacification of the gastrointestinal tract should be conside-
red.
(Grade 2+) STRONG agreement
Rationale: Computed tomography is often considered to
be the reference examination for the detection of postoper-
ative collections and abscesses [77]. It is very reliable after
the fifth postoperative day and, whenever possible, should
be contrast-enhanced to facilitate visualization of collec-
tions. When an anastomotic fistula is suspected, gastroin-
testinal opacification with a water-soluble contrast agent is
essential [78]. The reported sensitivity of this examination in
abdominal infectious emergencies is 73 to 94% depending
on the disease and its specificity is higher than 95% [79]. The
diagnostic value of various radiological examinations was
compared in a series of postoperative peritonitis [80]: an
accurate prediction was provided by computed tomography
in 97.2% of cases, contrast-enhanced radiological examina-
tions in 66.2% of cases and ultrasound examinations in
44.3% of cases [80]. Not all abdominopelvic collections
are abscesses. Fine-needle aspiration of the collection
is necessary in doubtful cases and allows bacteriological
examination.
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R33 – In the absence of clinical or laboratory improvement 4 to
5 days after the index surgery, noncontributive computed
tomography cannot exclude persistent intra-abdominal infec-
tion.
(Expert opinion) STRONG agreement
Rationale: The essential challenge of management is to
accurately identify patients requiring relaparotomy without
delaying reoperation. The decision to perform relaparotomy
is based on a combination of clinical, laboratory and radiological
criteria which, taken separately, do not have any positive pre-
dictive value for reoperation, as well as the team’s experience
[73,77,81].
Computed tomography is often considered to be the refer-
ence examination for the detection of postoperative collections
and abscesses [77]. It is very reliable after the fifth postopera-
tive day and, whenever possible, should be contrast-enhanced
to facilitate visualization of collections. In case when a post-
operative complication is suspected during the early postop-
erative course (first three days), the decision to perform
relaparotomy can be taken without imaging in a context of
unexplained clinical deterioration [81]. After the third day, the
decision to perform relaparotomy must be validated by imag-
ing, primarily computed tomography. However, a ‘‘normal’’ or
noncontributive CT examination cannot exclude a diagnosis of
persistent intra-abdominal infection.
R34 – Biomarkers should probably not be used for the
diagnosis of persistent intra-abdominal infection.
(Grade 2–) STRONG agreement
Rationale: Only five studies directly concerned evaluation of
a biomarker following the management of secondary perito-
nitis [82–86] between 2004 and 2009. Three studies evaluated
procalcitonin [84–87], one study evaluated C-Reactive Protein
[83,87] and one study evaluated s-TREM 1 [82]. Two retrospec-
tive studies assessed the predictive value of the biomarker for
the development of repeated or persistent peritoneal infection
[82,84], and three other studies assessed the predictive value of
the biomarker in other complications such as multiple organ
failure [85] and mortality [83] or postoperative morbidity
[86]. All of these studies, presenting methodological limita-
tions and based on small sample sizes, failed to demonstrate
the discriminant value of the biomarker evaluated. Finally, no
study has assessed the value of a biomarker to adjust the
duration of antibiotic therapy.
7.2. When and how should microbiological specimens be obtained?
R35 – First-line image-guided diagnostic fine-needle aspira-
tion should probably be proposed for microbiological
examination of intra-abdominal collections in a context of
healthcare-associated infections and when there is a doubt
about the diagnosis.
(Expert opinion) STRONG agreement
Rationale: Ultrasound and computed tomography imaging
allow the diagnosisofcollectionsand effusions,visualize the site
of the collection and adjacent anatomical structures and can
distinguish simple collections from complex collections. How-
ever, imaging is unable to predict the nature of the collection or
the presence of superinfection. Not all abdominopelvic collec-
tions are abscesses. Diagnostic fine-needle aspiration can be
performed for microbiological (bacterial and fungal) examina-
tion of small collections(less than 3 cm), orwhen there isa doubt
about the nature of the collection.
R36 – Blood cultures and peritoneal fluid samples must be
taken in healthcare-associated IAI for bacterial and fungal
identification and antibiotic susceptibility testing.
(Expert opinion) STRONG agreement
Rationale: No study has ever specifically assessed the value
of microbiological examination in healthcare-associated IAI.
Antibiotic susceptibility testing is recommended to adapt
empirical antibiotic therapy. Inappropriate empirical therapy
is common [88–90] and has been reported by some authors to
be a risk factor for excess morbidity and mortality [88]. Direct
examination of samples after Gram stain cannot predict the
results of culture and only provides information likely to
modify the patient’s management when yeasts are demon-
strated [29].
R37 – Direct examination of peritoneal fluid looking for yeasts
should probably be performed in healthcare-associated IAI.
(Grade 2+) STRONG agreement
Rationale: Direct examination of samples after Gram stain
cannot predict the results of culture and only provides
information likely to modify the patient’s management
when yeasts are demonstrated [29]. Direct examination
cannot reliably determine the pathogenic nature of yeasts,
but a positive examination suggests local proliferation in
favour of active infection. The morphological appearance of
the fungus (budding, filamentous, etc.) is not clinically
relevant. In a study comprising 83 cases of peritonitis
admitted to intensive care with cultures of intraoperative
samples positive for Candida, the authors reported excess
mortality (OR = 4.7; 95% CI 1.2–19.7; P = 0.002) when yeasts
were detected on direct examination [29]. These findings
argue in favour of empirical antifungal therapy based on
direct examination.
7.3. How should empirical antibiotic therapy be targeted?
R38 – A first episode of healthcare-associated IAI is associated
with a high-risk of multi-drug resistant bacteria in the
following settings: antibiotic therapy during the 3 months
preceding hospitalisation and/or > 2 days preceding the first
infectious episode and/or an interval > 5 days between the
index operation and reoperation.
(Grade 1+) STRONG agreement
Rationale: Only limited data are available concerning
predictive factors for intra-abdominal infection (IAI) due to
multi-drug resistant (MDR) bacteria. Previous antibiotic ther-
apy (for more than 48 hours during the previous 2 weeks
[26]) or during the previous 3 months [90] and length of
hospital stay or reoperation interval greater than 5 days
[26,90] have been identified as independent risk factors for
MDR IAI. In a study based on 100 cases of postoperative
peritonitis, 41 episodes were due to at least one MDR strain
[91]. The presence of antibiotic therapy for at least 24 hours
between the index operation and reoperation for POP were
also the major risk factor for MDR infection [91]. These
studies showed that the presence of resistant Enterobacter-
iaceae is influenced by previous antibiotic therapy. However,
the practical implications of these results remain limited, as
these risk factors are neither very sensitive nor very specific
[92].
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R39 – In patients known to be infected by 3GC-resistant
Enterobacteriaceae, ampicillin- and/or vancomycin-resistant
enterococci or methicillin-resistant Staphylococcus aureus
(MRSA), these strains should probably be taken into account
in the empirical antibiotic therapy for healthcare-associated
peritonitis.
(Grade 2+) STRONG agreement
Rationale: In the case of severe infection or septic shock,
inappropriate empirical anti-infective therapy (not covering all
of the microorganisms isolated) is regularly associated with
poorer survival [88,93]. In healthcare-associated peritonitis,
empirical antibiotic therapy must be defined as a function data
of local microbial epidemiology. The most difficult microor-
ganisms to treat are usually 3GC-resistant Enterobacteriaceae,
ampicillin- and/or vancomycin-resistant enterococci and meth-
icillin-resistant S. aureus [26,88–91]. Dual antibiotic therapy is
justified to extend the spectrum of activity in order to minimize
the risk of therapeutic impasse [91]. Only limited data are
available concerning the frequency of and risk factors for
isolation of ampicillin-resistant Enterococcus faecium in IAI
[7,94,95]. The presence of these bacteria would justify empiri-
cal administration of glycopeptides, particularly in patients
with septic shock or severe sepsis. Glycopeptide-resistant
E. faecium in IAI has essentially been observed, to date, in
epidemic settings and/or in a context of known colonization.
Empirical coverage is only recommended in the case of VRE
colonization and septic shock or severe sepsis related to IAI.
The frequency of methicillin-resistant S. aureus (MRSA) intra-
abdominal infection is low. Nasal and/or skin colonization is a
risk factor for postoperative IAI due to the same bacteria [92].
7.4. Should enterococci be taken into account in anti-infective
therapy?
R40 – Empirical antibiotic therapy active against ampicillin-
resistant enterococcus (vancomycin or even tigecycline)
should probably be prescribed in patients with nosocomial
peritonitis presenting risk factors for IAI due to these bacteria
(hepatobiliary disease, liver transplant, ongoing antibiotic
therapy).
(Grade 2+) STRONG agreement
Rationale: Healthcare-associated infections are associated
with a high incidence of enterococci, which are isolated in
about 30 to 40% of cases [7,8,39,92,96]. The presence of
enterococci in peritoneal fluid is associated with increased
morbidity [3,27,39,95,96] and mortality [3,7,8,39,94], especially
due to the expression of virulence factors by most strains of
enterococci [94]. This excess morbidity and mortality has been
contested by some authors in patients with no signs of organ
failure [40]. Some risk factors for enterococcal IAI have been
identified: immunodepression, previous antibiotic therapy
with cephalosporins or broad-spectrum beta-lactam antibio-
tics [39,92]. The presence of these risk factors must be taken
into account in the choice of empirical antibiotic therapy. In
patients in septic shock or severe sepsis, empirical antibiotic
therapy must cover enterococci. The majority of the available
therapeutic data concern vancomycin [7,91]. Several studies
have reported the use of tigecycline [45–47].
7.5. Should yeasts be taken into account in anti-infective therapy?
R41 – Empirical antifungal therapy (echinocandins in the case
of serious infection) should probably be initiated in health-
care-associated IAI when a yeast is detected on direct
examination. Antifungal therapy (echinocandins in the case
of serious infection or fluconazole-resistant strains) should
probably be initiated in all cases of healthcare-associated IAI
in which peritoneal fluid culture (apart from closed succion
drains and drainage systems, etc.) is positive for yeasts.
(Grade 2+) STRONG agreement
Rationale: No prospective study has confirmed the need for
empirical antifungal therapy. The presence of yeasts on direct
examination of peritoneal fluid was a risk factor for mortality in
a cohort study of patients admitted to intensive care for severe
peritonitis [29]. Isolation of yeasts from peritoneal fluid in
postoperative peritonitis has been associated with excess
mortality [8]. This excess mortality was also observed in a
case-control study of patients matched for age, site of infection
and IGS II score [35]. On the basis on these findings, empirical
antifungal therapy should probably be initiated in patients with
healthcare-associated IAI and septic shock or severe sepsis.
Antifungal therapy must target Candida spp. (albicans or non-
albicans) by means of an echinocandin or fluconazole [54]. An-
tifungal therapy can be stopped in the absence of yeast on
peritoneal fluid culture and antifungal susceptibility testing
guides the definitive treatment. Echinocandins are proposed as
empirical therapy for severe forms and as definitive treatment
for severe forms and in the presence of fluconazole-resistant
strains (C. glabrata and C. krusei). The optimal duration of
definitive treatment has not been established.
7.6. What empirical anti-infective therapy should be prescribed and in
which patients?
R42 – A combination of piperacillin/tazobactam + amikacin
(optional in the absence of signs of severity) should probably
be used as empirical antibiotic therapy for a first episode of
healthcare-associated IAI in the absence of any risk factors for
MDR infection. In the presence of at least two of the six criteria
defined below, the patient is at high-risk of MDR infection and
a broad-spectrum carbapenem (imipenem or meropene-
m) + amikacin (optional in the absence of signs of severity)
should probably be used. In patients with septic shock, only
1 of the six criteria defined below is sufficient to justify a
combination of broad-spectrum carbapenem + amikacin. The
following six criteria are risk factors for MDR infection: (1)
Treatment with a 3rd generation cephalosporin or fluoroqui-
nolone (including a single dose) during the previous 3 months;
(2) Isolation of extended-spectrum beta-lactamase-producing
Enterobacteriaceae or ceftazidime-resistant P. aeruginosa on
a sample obtained during the previous 3 months, regardless of
the site; (3) Hospitalisation in a foreign country during the
previous 12 months; (4) Patient living in a nursing home or
long-stay care AND with an indwelling catheter and/or
gastrostomy; (5) Failure of broad-spectrum antibiotic therapy
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with a 3rd generation cephalosporin or fluoroquinolone or
piperacillin-tazobactam; (6) Early recurrence (< 2 weeks) of an
infection treated by piperacillin-tazobactam for at least 3 days.
(Grade 2+) STRONG agreement
Rationale: Empirical antibiotic therapy must be defined as a
function of local epidemiological data and previous antibiotic
treatments. Bacterial resistance varies from one study to
another (15 to 47%, at the time of the first infectious episode)
[7,26,90–92] and increases over time with the number of
reoperations (75% at the time of the third reoperation accord-
ing to Seguin et al. [90]), with an increased risk of isolating
ESBL-producing Enterobacteriaceae, cephalosporinase-over-
producing/derepressed Enterobacteriaceae, multi-drug resis-
tant non-fermenting Gram-negative bacilli, methicillin-
resistant S. aureus or amoxicillin-resistant E. faecium. Multi-
drug resistant bacteria requiring broad-spectrum antibiotic
therapy are isolated in 20 to 40% of cases, depending on the
definitions used. Gram-negative bacteria generally remain
susceptible to carbapenems, while ESBL-producing bacteria
are inconstantly susceptible to aminoglycosides (50–60%)
[7]. In a study on 100 cases of postoperative peritonitis,
Augustin et al. showed that combinations of amikacin with
piperacillin/tazobactam or imipenem were the most effective
regimens to target the bacteria isolated from peritoneal sam-
ples in patients who had received broad-spectrum antibiotic
therapy between the index surgery and reoperation [91].
R43 – One of the following combinations should probably be
used in patients with healthcare-associated infections and
documented beta-lactam allergy: (1) ciprofloxacin + amikacin +
metronidazole + vancomycin; (2) aztreonam + amikacin + van-
comycin + metronidazole; (3) when no other treatment options
are available, tigecycline + ciprofloxacin.
(Expert opinion) STRONG agreement
Rationale: Only limited data are available on this subject in
the literature and no clinical trial supports the published guide-
lines in the case of beta-lactam allergy.
The ciprofloxacin–amikacin–vancomycin–metronidazole
combination targets all bacteria encountered in intra-abdomi-
nal infections. Fluoroquinolones, which are routinely banned
due to the risk of selection of resistant mutants, can be
proposed in patients with a documented history of serious
allergy to beta-lactam antibiotics contraindicating the use of
these agents [41,44].
Aztreonam can be used in the case of beta-lactam allergy, but,
as it fails to cover streptococci and staphylococci, it must be
combined with an antibiotic active on Gram positive cocci and
obligate anaerobes. The aztreonam–amikacin–vancomycin–
metronidazole combination covers all bacteria encountered in
intra-abdominal infections and has the advantage of combining
three narrow spectrum antibiotics. The activity of aztreonam on
Enterobacteriaceae is at least equal to that of ceftazidime on
Enterobacteriaceae and P. aeruginosa. Combinations including
aztreonam may be ineffective in the case of ESBL-producing
strains.
Tigecycline is active on E. coli and ESBL+ Klebsiella spp., but
is insufficiently active against the Protea group of Enterobac-
teriaceae and P. aeruginosa [45–47].
7.7. What is the optimal duration of anti-infective therapy?
R44 – Antibiotic therapy for postoperative or nosocomial IAI
should probably be administered for 5 to 15 days.
(Expert opinion) STRONG agreement
Rationale: The duration of antibiotic therapy has not been
extensively evaluated. Seguin et al. [26], in a series of patients
with community-acquired and nosocomial peritonitis,
reported a duration of treatment of 15  8 days in patients
with MDR infection and 10  4 days in patients without MDR
infection. In a recent study, Augustin et al. reported a duration
of treatment of 10  4 to 12  6 days according to whether
empirical therapy was appropriate or inappropriate [91]. MDR
strains were mainly isolated from patients who had received
broad-spectrum antibiotics in the interval between the two
operations [90,91].
Appendix A. Supplementary data
Supplementary data (Figs. 1–3) associated with this article can
be found, in the online version, at doi:10.1016/j.accpm.2015.03.
005.
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